NASDAQ:MGEN

Miragen Therapeutics Stock Forecast, Price & News

$22.78

-2.15 (-8.62 %)

(As of 01/15/2021 01:54 PM ET)

Add

Compare

Today's Range

$22.30

Now: $22.78▼

$24.00

50-Day Range

$16.21

MA: $18.05▼

$22.33

52-Week Range

$4.66

Now: $22.78▼

$34.05

Volume5,677 shs

Average Volume149,044 shs

Market Capitalization$89.02 million

P/E RatioN/A

Dividend YieldN/A

Beta1.66

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

MarketRank^™

Overall MarketRank^™

1.28 out of 5 stars

Medical Sector

595th out of 1,480 stocks

Medical Laboratories Industry

11th out of 29 stocks

1.4 Analyst's Opinion

Consensus Rating
Miragen Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.33, Miragen Therapeutics has a forecasted downside of 28.3% from its current price of $22.78.
Amount of Analyst Coverage
Miragen Therapeutics has only been the subject of 3 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Miragen Therapeutics has received 267 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Miragen Therapeutics has received 225 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Miragen Therapeutics has received 54.27% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote “Outperform” if you believe MGEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Miragen Therapeutics does not currently pay a dividend.
Dividend Growth
Miragen Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Miragen Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,271,738.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.10% of the stock of Miragen Therapeutics is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Miragen Therapeutics are expected to grow in the coming year, from ($9.97) to ($9.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Miragen Therapeutics is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Miragen Therapeutics is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Miragen Therapeutics has a P/B Ratio of 3.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Medical laboratories

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MGEN

Previous Symbol

CUSIPN/A

CIK1590750

Webwww.signalgenetics.com

Phone720-643-5200

Employees45

Debt

Debt-to-Equity Ratio0.20

Current Ratio4.23

Quick Ratio4.23

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.46 million

Price / Sales19.96

Cash FlowN/A

Price / Cash FlowN/A

Book Value$6.78 per share

Price / Book3.36

Profitability

EPS (Most Recent Fiscal Year)($20.09)

Net Income$-41,870,000.00

Net Margins-1,393.50%

Return on Equity-141.66%

Return on Assets-88.74%

Miscellaneous

Outstanding Shares3,908,000

Market Cap$89.02 million

Next Earnings Date3/10/2021 (Estimated)

OptionableNot Optionable

$22.78

-2.15 (-8.62 %)

(As of 01/15/2021 01:54 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive MGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.

Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions

How has Miragen Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Miragen Therapeutics' stock was trading at $0.6119 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MGEN stock has increased by 3,622.8% and is now trading at $22.78.
View which stocks have been most impacted by COVID-19.

Is Miragen Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Miragen Therapeutics stock.
View analyst ratings for Miragen Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Miragen Therapeutics?

Wall Street analysts have given Miragen Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Miragen Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Miragen Therapeutics' next earnings date?

Miragen Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Miragen Therapeutics.

How were Miragen Therapeutics' earnings last quarter?

Miragen Therapeutics, Inc. (NASDAQ:MGEN) posted its earnings results on Tuesday, November, 10th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.03. Miragen Therapeutics had a negative return on equity of 141.66% and a negative net margin of 1,393.50%.
View Miragen Therapeutics' earnings history.

What price target have analysts set for MGEN?

6 brokers have issued 12-month price objectives for Miragen Therapeutics' stock. Their forecasts range from $6.00 to $37.00. On average, they anticipate Miragen Therapeutics' stock price to reach $16.33 in the next year. This suggests that the stock has a possible downside of 28.3%.
View analysts' price targets for Miragen Therapeutics or view Wall Street analyst' top-rated stocks.

Are investors shorting Miragen Therapeutics?

Miragen Therapeutics saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 161,700 shares, a decrease of 14.2% from the December 15th total of 188,500 shares. Based on an average daily trading volume, of 446,900 shares, the short-interest ratio is presently 0.4 days. Approximately 4.4% of the shares of the stock are short sold.
View Miragen Therapeutics' Short Interest.

Who are some of Miragen Therapeutics' key competitors?

Some companies that are related to Miragen Therapeutics include Progenity (PROG), Centogene (CNTG), Exagen (XGN), Enzo Biochem (ENZ), Celcuity (CELC), Biocept (BIOC), AnPac Bio-Medical Science (ANPC), OpGen (OPGN), Psychemedics (PMD), CannLabs (CANL), American Shared Hospital Services (AMS), Cancer Genetics (CGIX), American Shared Hospital Services (AMS), Avant Diagnostics (AVDX) and PotNetwork (POTN).
View all of MGEN's competitors.

What other stocks do shareholders of Miragen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Miragen Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Novan (NOVN) and Aeterna Zentaris (AEZS).

Who are Miragen Therapeutics' key executives?

Miragen Therapeutics' management team includes the following people:

Mr. Jason A. Leverone CPA, CPA, CFO, Sec. & Treasurer (Age 46, Pay $355k)
Dr. William Stuart Marshall Ph.D., Co-Founder & Sr. Technical Advisor (Age 56, Pay $521k)
Dr. Diana Escolar, Chief Medical Officer (Age 58, Pay $484.38k)
Ms. Lee M. Rauch, CEO & Director (Age 65)
Dr. Jonathan Violin Ph.D., Pres & COO (Age 45)
Eric N. Olson, Co-Founder & Chairman of Scientific Advisory Board
Dr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 75)
Dr. Marvin H. Caruthers, Co-Founder & Scientific Advisory Board Member (Age 80)
Mr. Vahe Bedian Ph.D., Chief Scientific Officer
Dr. Aimee L. Jackson, VP of Research

What is Miragen Therapeutics' stock symbol?

Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."

How do I buy shares of Miragen Therapeutics?

Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Miragen Therapeutics' stock price today?

One share of MGEN stock can currently be purchased for approximately $22.78.

How big of a company is Miragen Therapeutics?

Miragen Therapeutics has a market capitalization of $89.02 million and generates $4.46 million in revenue each year. The medical research company earns $-41,870,000.00 in net income (profit) each year or ($20.09) on an earnings per share basis. Miragen Therapeutics employs 45 workers across the globe.

What is Miragen Therapeutics' official website?

The official website for Miragen Therapeutics is www.signalgenetics.com.

How can I contact Miragen Therapeutics?

Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here